Balchem Continues to Soar: Record-Breaking Q3 Results and Exciting Scientific Developments
Yesterday, Balchem Corporation hosted its third quarter 2026 earnings call, revealing yet another impressive set of results. The company's Chief Financial Officer, Martin Bengtsson, and Chairman, President, and CEO, Ted Harris, shared the details of Balchem's healthy growth across all three reporting segments.
The quarter saw record consolidated sales, net earnings, and adjusted EBITDA, as well as solid cash flows. This continued success is attributed to Balchem's unique portfolio of specialty nutrients and delivery systems, which have captured a significant share of the market. The favorable better-for-you trends within the food and nutrition markets also align with the company's product offerings and capabilities.
As a result, Balchem's Human Nutrition & Health segment has seen solid demand growth for its unique portfolio of ingredients and solutions. Consumer interest in supplementation and better-for-you food systems continues to support a healthy market environment for the company. In Animal Nutrition & Health, momentum is building as customers adopt Balchem's nutrient technologies to improve animal health and productivity.
The Specialty Products segment has also seen healthy market demand for its specialized performance gases and services. Overall, Balchem sees a positive demand outlook and remains confident in its ability to deliver healthy growth over the long term.
But it's not just about the numbers – Balchem is also making significant strides in scientific research. Chairman Ted Harris highlighted two recently published studies that provide exciting new evidence for the company's branded ingredients, VitaCholine and K2VITAL. The first study, led by MD Anderson, evaluated the potential benefits of choline supplementation in cognitively healthy APOE4 carriers – a population at increased genetic risk for developing Alzheimer's disease.
The findings provide encouraging new evidence that may support the role of VitaCholine in lifelong brain health and further strengthen the scientific foundation of choline in healthy aging and cognition. This represents another important step in positioning VitaCholine as an essential nutrient and a leading science-backed ingredient in adult cognitive health.
The second study, DANCODE, published in Circulation, examined the impact of vitamin K2 supplementation using Balchem's K2VITAL DELTA on coronary artery calcification and cardiovascular health. The findings add important clinical evidence supporting the role of vitamin K2 in cardiovascular health and healthy aging while further strengthening the scientific leadership and commercial differentiation of the company's K2VITAL platform.
These exciting developments demonstrate Balchem's commitment to innovation, science, and customer satisfaction. As the company continues to break records and push the boundaries of what is possible, one thing is certain – Balchem is a true leader in the specialty nutrients industry.
